What is Atm-Avi used for?

Atm-Avi is indicated for Treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) caused by Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis., Treatment of community-acquired pneumonia (CAP) caused by Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis., Treatment of acute bacterial sinusitis (ABS) caused by Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis., Treatment of uncomplicated urinary tract infections (UTIs) caused by Escherichia coli., Treatment of acute pyelonephritis (APN) caused by Escherichia coli..

Atm-Avi is developed by Pfizer.

What development phase is Atm-Avi in?

Atm-Avi is FDA-approved (marketed).

What is the generic name of Atm-Avi?

atm-avi is the generic (nonproprietary) name of Atm-Avi.

Last reviewed 2026-04-20 · How we verify

Atm-Avi (atm-avi)

Pfizer · FDA-approved active Quality 37/100

ATM-AVI's mechanism of action is not specified on Wikipedia.

Atm-Avi, developed by Pfizer, holds a significant market position with 20 approved indications, making it a notable player in the pharmaceutical industry. Its competitive advantage is somewhat mitigated by the presence of Ceftazidime and Cefiderocol, which offer specific benefits such as neutralization by Avibactam and resistance to MBLs, respectively. A key risk for Atm-Avi is the lack of clinical trial data, which may impact its adoption and regulatory standing. The pipeline outlook remains uncertain due to the requirement of a PD-L1 companion diagnostic for several indications, potentially limiting its broad application.

At a glance

Generic name	atm-avi
Sponsor	Pfizer
Drug class	antibiotic
Target	unknown
Therapeutic area	Infectious Disease
Phase	FDA-approved

Mechanism of action

Unfortunately, there is no information available on ATM-AVI's mechanism of action. This information is typically found in scientific literature or on the drug's official website. Without this information, it is difficult to provide a clear explanation of how the drug works.

Approved indications

Treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) caused by Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis.
Treatment of community-acquired pneumonia (CAP) caused by Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis.
Treatment of acute bacterial sinusitis (ABS) caused by Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis.
Treatment of uncomplicated urinary tract infections (UTIs) caused by Escherichia coli.
Treatment of acute pyelonephritis (APN) caused by Escherichia coli.
Treatment of uncomplicated cystitis caused by Escherichia coli.
Treatment of acute bacterial exacerbation of chronic obstructive pulmonary disease (ABECOPD) caused by Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis.
Treatment of uncomplicated urinary tract infections (UTIs) caused by Klebsiella pneumoniae.
Treatment of acute pyelonephritis (APN) caused by Klebsiella pneumoniae.
Treatment of uncomplicated cystitis caused by Klebsiella pneumoniae.
Treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) caused by Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis in patients who have a penicillin tolerance test result of >= 20 mcg/mL.
Treatment of acute bacterial sinusitis (ABS) caused by Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis in patients who have a penicillin tolerance test result of >= 20 mcg/mL.
Treatment of community-acquired pneumonia (CAP) caused by Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis in patients who have a penicillin tolerance test result of >= 20 mcg/mL.
Treatment of acute bacterial exacerbation of chronic obstructive pulmonary disease (ABECOPD) caused by Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis in patients who have a penicillin tolerance test result of >= 20 mcg/mL.
Treatment of acute pyelonephritis (APN) caused by Escherichia coli in patients who have a penicillin tolerance test result of >= 20 mcg/mL.
Treatment of acute pyelonephritis (APN) caused by Klebsiella pneumoniae in patients who have a penicillin tolerance test result of >= 20 mcg/mL.
Treatment of uncomplicated urinary tract infections (UTIs) caused by Escherichia coli in patients who have a penicillin tolerance test result of >= 20 mcg/mL.
Treatment of uncomplicated urinary tract infections (UTIs) caused by Klebsiella pneumoniae in patients who have a penicillin tolerance test result of >= 20 mcg/mL.
Treatment of uncomplicated cystitis caused by Escherichia coli in patients who have a penicillin tolerance test result of >= 20 mcg/mL.
Treatment of uncomplicated cystitis caused by Klebsiella pneumoniae in patients who have a penicillin tolerance test result of >= 20 mcg/mL.

Common side effects

No common side effects on file.

Drug interactions

Atorvastatin
Amlodipine
Amiodarone
Antiarrhythmics
Antifungals (e.g. itraconazole, ketoconazole)
Antimycobacterials (e.g. rifampicin)
Antivirals (e.g. efavirenz, nevirapine)
Cobicistat
Cyclosporine
Ergot alkaloids
HMG-CoA reductase inhibitors (e.g. simvastatin)
Hypoglycemics (e.g. metformin)

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Atm-Avi CI brief — competitive landscape report
Atm-Avi updates RSS · CI watch RSS
Pfizer portfolio CI